ClinicalTrials.gg
RecruitingNCT06496282Updated Jul 11, 2024

Lemborexant on Improving Sleep Quality Among Hospital Rotating Shift Workers

A Phase 3 interventional study of Lemborexant and Placebo in Sleep, sponsored by Phramongkutklao College of Medicine and Hospital. Recruiting at 1 site in Thailand. Open to participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by Phramongkutklao College of Medicine and Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

Shift Work Sleep Disorder (SWSD) are caused by working shifts with a wake-up schedule and sleeping in a way that is different from the natural way of sleeping and avoiding sleep usually results in deviations. of the biological clock (Biological clock), which is an important cause of sleep problems including insomnia, excessive sleepiness or daytime sleepiness these problems was associated cadiovascular events, decrease quality of life and long term working. At the present there are limited information regarding the effectiveness of medications used to promote sleep in shift workers. Lemborexant is specific in binding to orexin type 2, which has a direct effect on sleep. and there are limited biomarkers monitoring from the use of lemborexant including still not found. Which studies have followed depressive symptoms, anxiety symptoms and cognition from a group of people with insomnia, the aim of study to assessment effectiveness of lemborexant on sleep efficiency, quality of life, symptoms of depression, cognition, BDNF, CRP, IL-6 and TNF-alpha levels. of volunteers working on rotating shifts.

02

Conditions studied

  • Sleep

Keywords

  • Shift workers
  • Improving sleep
  • Lemborexant
  • Orexin receptor antagonists
  • Hospital rotating shift workers
  • Rotating shift workers
03

In context

Lead sponsor

Phramongkutklao College of Medicine and Hospital is the lead sponsor of 37 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 20-60 years
  • Rotating shift workers at least 3 months and continue rotating shift until end of study
  • Participants who have sleep problem especially total sleep time lower than 6 hours and/or unable to sleep effectively according to the ICSD-3 at least 1 criteria
  • Participants who have sleepy while working and have Epworth sleepiness scale in shift grater than or equal to 10 points

Exclusion criteria

Exclusion Criteria:

  • Receiving drug interaction esp. drugs induced (moderate to severe) or drugs inhibited CYP3A4 (moderate to severe)
  • Untreatment mental health disease or in process medication adjustment
  • Hepatic function in Chid-Pugh C
  • Pregnancy
  • Breastfeeding
  • Participants who in process medication adjustment such as mental heat, neurology, insomnia, drugs.
  • Diagnosis obstructive sleep apnea (OSA) with or without CPAP using or diagnosis restless leg syndrome or circadian rhythm disorders or narcolepsy
  • Complex sleep behaviors such as sleep driving, sleep phone, sleep cooking
  • HAM-D grater than or equal to 24 points
  • HAM-A grater than or equal to 24 points
  • Caffeine taking grater than 400 mg/day or can't not hold caffeine 4 hours before bedtime
  • Substance abuse or alcoholism within 2 years ago
  • Alcohol intake grater than 140 g of alcohol per week in female or intake grater than 210 g of alcohol per week in male or can't control alcohol drinking greater than 20 g of alcohol per day or can't hold alcohol within 3 hours before bedtime
  • Cannabinoid using within 1 week ago
  • Participants who have underlying disease such as stroke, atrial fibrillation, , hepatic impairment, severe renal impairment, cognitive impairment, cancer, chronic pain
  • Participant who use of benzodiazepine or non-benzodiazepine in treatment of insomnia
  • Participant who have nocturia problem
  • Participant who have mental health problem which the physician conclude it affect the safety of participant
  • Participant who have suicidal thinking with or without plan or have suicidal behaviors within 10 years ago
  • Participant who have major surgery schedule during the study
  • Travel across greater than 3 time zone within 2 weeks before include participant
  • Allergy of lemborexant or component of lemborexant
  • Have previously participated in study that used lemborexant
  • Participant who
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Lemborexant 5 mg

    Lemborexant 5 mg 1 tab hs before bedtime

    Drug: Lemborexant

  • Placebo comparator
    Placebo

    Placebo of Lemborexant 5 mg 1 tab hs before bedtime

    Drug: Placebo

Interventions

  • The participants will receive lemborexant for improving sleep quality at lease 30 days in 6 weeks of study

    Also known as: Dayvigo

  • DrugPlacebo

    The participants will receive placebo for improving sleep quality at lease 30 days in 6 weeks of study

    Also known as: Dayvigo placebo

06

What researchers measure

Primary outcomes

  1. Assessment effective of sleep quality in lemborexant 5 mg compare with placebo group

    Sleep quality improvement evaluated by physician with actigraphy (Fitbit inspire 2) after lemborexant administration in 3 and 6 week.

    Time frame: 1 week after screening, 3 and 6 weeks after lemborexant administration

  2. Changing of Brian-derived neurotropic (BDNF) in lemborexant 5 mg compare with placebo group

    Blood sample of BDNF changing in 1 week after screening and 6 weeks after lemborexant administration

    Time frame: 1 week after screening and 6 weeks after lemborexant administration

Secondary outcomes

  1. Assessment effective of sleepiness level in lemborexant 5 mg compare with placebo group

    Sleepiness level improvement evaluated by physician with Epworth sleepiness scale after lemborexant administration in 1 week after screening and 6 weeks after lemborexant administration

    Time frame: 1 week after screening and 6 weeks after lemborexant administration

  2. Assessment effective of sleep quality in lemborexant 5 mg compare with placebo group

    Sleep quality improvement evaluated by physician with Pittsburgh sleep quality index (PSQI) in 1 week after screening and 6 weeks after lemborexant administration

    Time frame: 1 week after screening and 6 weeks after lemborexant administration

  3. Assessment of depression symptoms in lemborexant 5 mg compare with placebo group

    Depression symptoms improvement evaluated by physician with Hamilton depression rating scale (HAM-D) after lemborexant administration in 1 week after screening and 6 weeks after lemborexant administration

    Time frame: 1 week after screening and 6 weeks after lemborexant administration

  4. Assessment of anxiety symptoms in lemborexant 5 mg compare with placebo group

    Anxiety symptoms improvement evaluated by physician with Hamilton anxiety rating scale (HAM-A) after lemborexant administration in 1 week after screening and 6 weeks after lemborexant administration

    Time frame: 1 week after screening and 6 weeks after lemborexant administration

  5. Assessment of cognition in lemborexant 5 mg compare with placebo group

    Cognition improvement evaluated by physician with Motreal cognitive assessment (MOCA), Grooved pegboard test and Digit symbol substitution test in1 week after screening and 6 weeks after lemborexant administration

    Time frame: 1 week after screening and 6 weeks after lemborexant administration

  6. Assessment of quality of life in lemborexant 5 mg compare with placebo group

    Quality of life improvement evaluated by physician with EuroQOL five dimensions questionnaires (EQ-5D )in 1 week after screening and 6 weeks after lemborexant administration

    Time frame: 1 week after screening and 6 weeks after lemborexant administration

  7. Changing of CRP, IL-6 and TNF-alpha in lemborexant 5 mg compare with placebo group

    Blood sample of CRP, IL-6 and TNF-alpha changing in 1 week after screening and 6 weeks after lemborexant administration

    Time frame: 1 week after screening and 6 weeks after lemborexant administration

07

Study locations

1 of 1 sites recruiting
  • Phramongkutklao Hospital
    Ratchathewi, Bangkok 10400, Thailand
    Recruiting
    • Tipvilai Taweepunturat, Pharm.D. · Contacttaribtip@gmail.com · 0822956659
    • Pasiri Sithinamsuwan, MD · Contactmailto:pasiripmk@gmail.com · 0832367772
    • Tipvilai Taweepunturat, Pharm.D. · Principal investigator
    • Abisith Dechachongjumroen, MD · Principal investigator
    • Wananwat Danworapong, MD · Principal investigator
    • Pasiri Sithinamsuwan, MD · Principal investigator
    • Juthathip Suphanklang, BCP · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2024; primary completion for May 2026, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Jul 11, 2024
StartEst.
Aug 2024
Primary completionEst.
May 31, 2026
CompletionEst.
Jul 2026
Last update
Jul 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06496282
Lead sponsor
Phramongkutklao College of Medicine and Hospital
Collaborators
Silpakorn University
Responsible party
Sponsor
First posted
Jul 11, 2024
Start date
Aug 2024 (estimated)
Primary completion
May 31, 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jul 11, 2024

Study contacts

Tipvilai Taweepunturat, Pharm.D.
Contact
taribtip@gmail.com
0822956659
Pasiri Sithinamsuwan, MD
Contact
pasiripmk@gmail.com
0832367772
Tipvilai Taweepunturat, Pharm.D.
study chair · Faculty of Pharmacy Siam University
Abisith Dechachongjumroen, MD
principal investigator · Phramongkutklao hospital and College of Medicine
Wananwat Danworapong, MD
principal investigator · Phramongkutklao hospital and College of Medicine
Juthathip Suphanklang, BCP
study director · Phramongkutklao hospital and College of Medicine
Pasiri Sithinamsuwan, MD
study director · Phramongkutklao hospital and College of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lemborexant

Start the discussion